Comparison of Rocuronium Induced Neuromuscular Blockade in Late Second Trimester Pregnant and Non-pregnant Women
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04253093|
Recruitment Status : Recruiting
First Posted : February 5, 2020
Last Update Posted : February 5, 2020
|Condition or disease|
Pregnancy induces physiological changes. Plasma volume, cardiac output, hepatic blood flow and protein binding are changed from the first trimester of pregnancy. These physiological changes give effect to the onset and duration of neuromuscular blocking drugs.
Rocuronium is a commonly used neuromuscular blocking drug categorized as FDA category B. Rocuronium is widely used for pregnant women. Previous studies have evaluated the onset and duration of rocuronium in postpartum women. Lately, the investigators have evaluated the onset and duration of rocuronium in early second trimester pregnant women and the duration was significantly longer in early second trimester women compared to non-pregnant women.
Since there is little research on the onset and duration of rocuronium in the late second trimester pregnant women, the investigators planned the present research.
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||50 participants|
|Target Follow-Up Duration:||1 Day|
|Official Title:||Comparison of Rocuronium Induced Neuromuscular Blockade in Late Second Trimester Pregnant and Non-pregnant Women|
|Actual Study Start Date :||August 1, 2019|
|Estimated Primary Completion Date :||October 1, 2020|
|Estimated Study Completion Date :||December 1, 2020|
- duration of rocuronium [ Time Frame: time measured to 25% recovery with T1 using Train of Four watch, assessed upto 1 hour ]time measured with TOFwatch-SX
- onset of rocuronium [ Time Frame: time measured to 0% depression of T1 using Train of Four watch, assessed upto 5 minutes ]time measured with TOFwatch-SX
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04253093
|Contact: InJung Junfirstname.lastname@example.org|
|Korea, Republic of|
|Kangnam sungshim hospital||Recruiting|
|Seoul, Korea, Republic of|
|Contact: Jun In-Jung|
|Study Chair:||Eunmi Choi||professor|